| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
ECUBLANS, Switzerland—Biotech company AC Immune announced it has entered into an exclusive licensing and research agreement with Genentech for the development of anti-beta-amyloid antibodies. The deal will hinge on the application of the Swiss company's SupraAntigen platform for developing conformation-specific antibodies.
 
"Out-licensing one of our lead programs to Genentech achieves a major business objective for the company and represents a significant milestone in the 3-year history of AC Immune," said Prof. Andrea Pfeifer, AC Immune CEO. "Genentech is an excellent, and our preferred, collaborator for the antibody program due to its expertise in development and commercialization of antibodies."
 
For its part, Genentech will provide the small biotech with an upfront payment and the potential for a total of $300 million in payments upon the achievement of clinical and regulatory milestones for Alzheimer's and other indications. AC Immune will also receive royalties on any products that make it to commercialization.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue